April 23, 2008 - Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, announced the start of a phase 1 clinical trial with its BiTE(R) antibody MT110. The study will explore the safety, pharmacokinetics, pharmacodynamics and anti-tumor activity of MT110 in patients with lung and gastrointestinal cancers. MT110 targets the epithelial cell adhesion molecule (EpCAM or CD326), which is highly expressed on colon, lung, breast, prostate, ovarian, gastric and pancreas cancers... Micromet's Press Release -
Apr 25, 2008
Micromet : Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
April 23, 2008 - Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, announced the start of a phase 1 clinical trial with its BiTE(R) antibody MT110. The study will explore the safety, pharmacokinetics, pharmacodynamics and anti-tumor activity of MT110 in patients with lung and gastrointestinal cancers. MT110 targets the epithelial cell adhesion molecule (EpCAM or CD326), which is highly expressed on colon, lung, breast, prostate, ovarian, gastric and pancreas cancers... Micromet's Press Release -
